← All trials
NCT05238025
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 19, 2022
- Primary completion
- Nov 30, 2023
- Completion date
- Dec 31, 2024
- First posted
- Feb 14, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 20000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bavarian NordicLead sponsor
- Bavarian NordicStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.